Novartis, CH0012005267

Erste Group raised its Novartis stock forecast to USD 9.24

Published on 10/14/2026 at 12:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Erste Group lifted FY2026 EPS forecast to USD 9.24 from USD 9.14. Novartis stock costs EUR 129.59 at Lang & Schwarz on October 14, 2026.

Forecast revision and launch progress

Rhapsido achieved a 29.30 percent complete response rate versus 14.00 percent for placebo on October 7, 2026.
Erste Group lifted its fiscal year 2026 earnings forecast to USD 9.24 from USD 9.14 on October 8, 2026.
Novartis stock traded at EUR 129.59 at 12:12 p.m. CEST at Lang & Schwarz on October 14, 2026.

Draufsicht auf Tabletten, Blisterpacks, Beipackzettel und Stethoskop auf weißem Untergrund — Novartis AG CH0012005267 – Flatlay mit generischen Tabletten, Blister, Beipackzettel und Stethoskop auf Weiß, Illustration mit AI erstellt.

Novartis (ISIN CH0012005267) drew a higher fiscal year 2026 earnings forecast of USD 9.24 from Erste Group, up from USD 9.14 in a note dated October 8, 2026, as reported by MarketBeat. The revision gives Novartis stock a concrete earnings catalyst ahead of the companys third-quarter report.

Three dated developments shape the story

On October 7, 2026, Novartis said the FDA approved Rhapsido for symptomatic dermographism, with complete hive resolution at Week 12 of 29.30 percent versus 14.00 percent for placebo. On October 7, 2026, Novartis also said it would present 46 multiple-sclerosis abstracts at MSToronto2026, according to GlobeNewswire. On October 8, 2026, Erste Group raised its fiscal year 2026 earnings forecast to USD 9.24 from USD 9.14, MarketBeat reported.

What does the forecast change mean?

The new estimate is 1.09 percent above Erste Groups previous forecast and 3.94 percent above the USD 8.89 consensus cited by MarketBeat. The operating backdrop is more mixed: for the quarter ending June 30, 2026, Novartis reported revenue of CHF 14.16 billion, down from CHF 14.84 billion a year earlier, while net profit fell to CHF 3.21 billion from CHF 4.04 billion, according to Markets Insider.

Analyst views remain divided. Barclays maintained a Hold rating and a CHF 130.00 target in a report dated October 13, 2026, according to Markets Insider.

When is the next company update?

Novartis lists its third-quarter 2026 financial results for October 27, 2026, with a webcast scheduled for 1:00 p.m. CET. That date is the next stated reporting milestone for investors.

Trading price and company facts

Novartis stock was trading at EUR 129.59 at Lang & Schwarz on October 14, 2026 at 12:12 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Novartis stock.